A Phase 2 Study of Tislelizumab in Combination With Other Drugs in People With Advanced Lung Cancer

Full Title

A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

Purpose

This study is assessing an immunotherapy called tislelizumab alone and with other medications in people with advanced lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that is inoperable (cannot be taken out with surgery).

People whose tumors contain high levels of a protein called PD-L1 will be randomly assigned to get one of these treatments:

• Tislelizumab alone
• Tislelizumab with BGB-A445, LBL-007, or another investigational immunotherapy (to be determined)

People whose tumors have low PD-L1 levels will be randomly assigned to one of these treatments:

• Tislelizumab with standard chemotherapy (carboplatin, cisplatin, paclitaxel, nab-paclitaxel, and pemetrexed)
• Tislelizumab with standard chemotherapy (carboplatin, cisplatin, paclitaxel, nab-paclitaxel, and pemetrexed) plus BGB-A445 or LBL-007
• Tislelizumab with standard chemotherapy (carboplatin, cisplatin, paclitaxel, nab-paclitaxel, and pemetrexed) plus another investigational immunotherapy drug (to be determined)

Who Can Join

To join this study, there are a few conditions. You must:

• Have NSCLC that is inoperable and has spread beyond its original location.
• Not have had treatment for advanced lung cancer. Any prior treatment must have finished at least 6 months before you get the study therapy.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call the office of Dr. Jamie Chaft at 646-608-3761 or Dr. Alissa Cooper at 646-608-4322.